BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 29989511)

  • 21. The effect of beclometasone dipropionate/formoterol extra-fine fixed combination on the peripheral airway inflammation in controlled asthma.
    Bulac S; Cimrin A; Ellidokuz H
    J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):82-7. PubMed ID: 25050594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of extrafine formulation of BDP/FF inhaler on asthma control, small airway function and airway inflammation among Mexican asthmatic patients. A retrospective analysis.
    Díaz-García R; Flores-Ramírez G; Ramírez-Oseguera RT
    Respir Med; 2020; 165():105932. PubMed ID: 32308205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High strength extrafine pMDI beclometasone/formoterol (200/6 μg) is effective in asthma patients not adequately controlled on medium-high dose of inhaled corticosteroids.
    Paggiaro P; Corradi M; Latorre M; Raptis H; Muraro A; Gessner C; Siergiejko Z; Scuri M; Petruzzelli S
    BMC Pulm Med; 2016 Dec; 16(1):180. PubMed ID: 27938358
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics, pharmacodynamics and safety of a novel extrafine BDP/FF/GB combination delivered via metered-dose inhaler in healthy Chinese subjects.
    Hu C; Miao J; Shu S; Wang Y; Zhu X; Luo Z
    Eur J Pharm Sci; 2020 Mar; 144():105198. PubMed ID: 31862312
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.
    Papi A; Vestbo J; Fabbri L; Corradi M; Prunier H; Cohuet G; Guasconi A; Montagna I; Vezzoli S; Petruzzelli S; Scuri M; Roche N; Singh D
    Lancet; 2018 Mar; 391(10125):1076-1084. PubMed ID: 29429593
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial.
    Vestbo J; Papi A; Corradi M; Blazhko V; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Singh D
    Lancet; 2017 May; 389(10082):1919-1929. PubMed ID: 28385353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose beclometasone dipropionate/formoterol fumarate in fixed-dose combination for the treatment of asthma.
    Corradi M; Spinola M; Petruzzelli S; Kuna P
    Ther Adv Respir Dis; 2016 Oct; 10(5):492-502. PubMed ID: 27340255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease.
    Singh D; Corradi M; Spinola M; Petruzzelli S; Papi A
    NPJ Prim Care Respir Med; 2016 Jun; 26():16030. PubMed ID: 27309985
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapid effects of extrafine beclomethasone dipropionate/formoterol fixed combination inhaler on airway inflammation and bronchoconstriction in asthma: a randomised controlled trial.
    O'Connor BJ; Collarini S; Poli G; Brindicci C; Spinola M; Acerbi D; Barnes PJ; Leaker B
    BMC Pulm Med; 2011 Dec; 11():60. PubMed ID: 22188731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pulmonary deposition of fluticasone propionate/formoterol in healthy volunteers, asthmatics and COPD patients with a novel breath-triggered inhaler.
    Kappeler D; Sommerer K; Kietzig C; Huber B; Woodward J; Lomax M; Dalvi P
    Respir Med; 2018 May; 138():107-114. PubMed ID: 29724381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of extrafine beclometasone/formoterol (BDP/F) on lung function, dyspnea, hyperinflation, and airway geometry in COPD patients: novel insight using functional respiratory imaging.
    De Backer J; Vos W; Vinchurkar S; Van Holsbeke C; Poli G; Claes R; Salgado R; De Backer W
    J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):88-99. PubMed ID: 25004168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ethnic Sensitivity Study of the Extrafine, Single-Inhaler, Triple Therapy Beclomethasone Dipropionate, Formoterol Fumarate, and Glycopyrronium Bromide Pressurized Metered Dose Inhaler in Japanese and Caucasian Healthy Individuals: A Randomized, Double-Blind, Single-Dose Crossover Study.
    Cella M; Täubel J; Delestre-Levai I; Tulard A; Vele A; Georges G
    Clin Ther; 2021 Nov; 43(11):1934-1947.e4. PubMed ID: 34600734
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Experimental and computational study of the effect of breath-actuated mechanism built in the NEXThaler
    Farkas Á; Lewis D; Church T; Tweedie A; Mason F; Haddrell AE; Reid JP; Horváth A; Balásházy I
    Int J Pharm; 2017 Nov; 533(1):225-235. PubMed ID: 28941830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of extrafine beclomethasone/formoterol for the treatment of chronic obstructive pulmonary disease: A non-interventional study in a Bulgarian population.
    Hodzhev VA; Kenderov AN; Ivanov YY; Gospodinova-Vulkova DP; Kalinov K
    Pulm Pharmacol Ther; 2022 Dec; 77():102169. PubMed ID: 36252915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting the Small Airways with Inhaled Corticosteroid/Long-Acting Beta Agonist Dry Powder Inhalers: A Functional Respiratory Imaging Study.
    Watz H; Barile S; Guastalla D; Topole E; Cocconi D; Mignot B; Belmans D; Duman D; Poli G; Fabbri LM
    J Aerosol Med Pulm Drug Deliv; 2021 Sep; 34(5):280-292. PubMed ID: 33944614
    [No Abstract]   [Full Text] [Related]  

  • 36. Bronchodilating effects of a new beclometasone dipropionate plus formoterol fumarate formulation via pressurized metered-dose inhaler in asthmatic children: a double-blind, randomized, cross-over clinical study.
    Pohunek P; Varoli G; Reznichenko Y; Mokia-Serbina S; Brzostek J; Kostromina V; Kaladze M; Muraro A; Carzana E; Armani S; Kaczmarek J
    Eur J Pediatr; 2021 May; 180(5):1467-1475. PubMed ID: 33404895
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An innovative corticosteroid/long-acting β
    Usmani O; Roche N; Marshall J; Danagher H; Price D
    Expert Opin Drug Deliv; 2019 Dec; 16(12):1367-1380. PubMed ID: 31752560
    [No Abstract]   [Full Text] [Related]  

  • 38. Pharmacokinetics of extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide in adolescent and adult patients with asthma.
    Kuna P; Jerzynska J; Martini M; Vele A; Barneschi I; Mariotti F; Georges G; Ciurlia G
    Pharmacol Res Perspect; 2022 Aug; 10(4):e980. PubMed ID: 35733414
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of inhaled extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide on distal and central airway indices, assessed using Functional Respiratory Imaging in COPD (DARWiIN).
    Skloot GS; Guasconi A; Lavon BR; Georges G; De Backer W; Galkin D; Cortellini M; Panni I; Bates JHT
    Respir Res; 2023 Oct; 24(1):244. PubMed ID: 37803368
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER.
    Singh D; Virchow JC; Canonica GW; Vele A; Kots M; Georges G; Papi A
    Respir Res; 2020 Oct; 21(1):285. PubMed ID: 33121501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.